People · Operator

Peter R. Young

Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals

1
Companies
2
Filings
$2.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Cel Sci CorpPharmaceuticalsSeed$2.5M$57.4M2017
Operator network

Peter R. Young at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Alexander G. Esterhazy · 1 companies · 1 sharedAlexander G. Este…Alexander R. Esterhazy · 1 companies · 1 sharedAlexander R. Este…Bruno R. Bailavoine · 1 companies · 1 sharedBruno R. Bailavoi…Bruno R. Baillavoine · 1 companies · 1 sharedBruno R. Baillavo…Daniel H. Zimmerman · 1 companies · 1 sharedDaniel H. Zimmerm…Daniel R. Zimmerman · 1 companies · 1 sharedDaniel R. Zimmerm…Eyal B. Talor · 1 companies · 1 sharedEyal B. TalorEyal R. Talor · 1 companies · 1 sharedEyal R. TalorGeert R. Kersten · 1 companies · 1 sharedGeert R. KerstenJohn H. Cipriano · 1 companies · 1 sharedJohn H. CiprianoJohn R. Cipriano · 1 companies · 1 sharedJohn R. CiprianoPatricia B. Prichep · 1 companies · 1 sharedPatricia B. Prich…Patricia R. Prichep · 1 companies · 1 sharedPatricia R. Prich…Cel Sci Corp · $2.5M raisedCel Sci CorpPeter R. YoungPY
Peter R. Young Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Peter R. Young on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Patricia R. Prichep11
Daniel R. Zimmerman11
Alexander R. Esterhazy11
Geert R. Kersten11
Bruno R. Bailavoine11
John R. Cipriano11
Eyal R. Talor11
Patricia B. Prichep11
Eyal B. Talor11
Bruno R. Baillavoine11
Daniel H. Zimmerman11
Alexander G. Esterhazy11
John H. Cipriano11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.